Bronchodilators in Symptomatic Tobacco-exposed Persons with Preserved Spirometry for the RETHINC Study Group
M. Han (Ann Arbor, United States), W. Ye (Ann Arbor, United States), D. Wang (Ann Arbor, United States), E. White (Ann Arbor, United States), M. Arjomandi (San Francisco, United States), I. Barjaktarevic (Los Angeles, United States), S. Brown (Baltimore, United States), R. Buhr (Los Angeles, United States), A. Comellas (Iowa City, United States), C. Cooper (Los Angeles, United States), G. Criner (Philadelphia, United States), M. Dransfield (Philadelphia, United States), F. Drescher (White River Junction, United States), R. Folz (Houston, United States), N. Hansel (Baltimore, United States), R. Kaner (New York, United States), R. Kanner (Salt Lake City, United States), J. Krishnan (Chicago, United States), S. Lazarus (San Francisco, United States), V. Maddipati (Greenville, United States), F. Martinez (New York, United States), A. Matthews (Durham, United States), C. Meldrum (Ann Arbor, United States), C. Mcevoy (Bloomington, United States), T. Nyunoya (Pittsburgh, United States), L. Rogers (New York, United States), W. Stringer (Los Angeles, United States), C. Wendt (Minneapolis, United States), R. Wise (Baltimore, United States), S. Wisniewski (Pittsburgh, United States), F. Sciurba (Pittsburgh, United States), P. Woodruff (San Francisco, United States)
Source: International Congress 2022 – ALERT 1: COPD and hospital management
Session: ALERT 1: COPD and hospital management
Session type: Clinical trials session
Number: 712
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Han (Ann Arbor, United States), W. Ye (Ann Arbor, United States), D. Wang (Ann Arbor, United States), E. White (Ann Arbor, United States), M. Arjomandi (San Francisco, United States), I. Barjaktarevic (Los Angeles, United States), S. Brown (Baltimore, United States), R. Buhr (Los Angeles, United States), A. Comellas (Iowa City, United States), C. Cooper (Los Angeles, United States), G. Criner (Philadelphia, United States), M. Dransfield (Philadelphia, United States), F. Drescher (White River Junction, United States), R. Folz (Houston, United States), N. Hansel (Baltimore, United States), R. Kaner (New York, United States), R. Kanner (Salt Lake City, United States), J. Krishnan (Chicago, United States), S. Lazarus (San Francisco, United States), V. Maddipati (Greenville, United States), F. Martinez (New York, United States), A. Matthews (Durham, United States), C. Meldrum (Ann Arbor, United States), C. Mcevoy (Bloomington, United States), T. Nyunoya (Pittsburgh, United States), L. Rogers (New York, United States), W. Stringer (Los Angeles, United States), C. Wendt (Minneapolis, United States), R. Wise (Baltimore, United States), S. Wisniewski (Pittsburgh, United States), F. Sciurba (Pittsburgh, United States), P. Woodruff (San Francisco, United States). Bronchodilators in Symptomatic Tobacco-exposed Persons with Preserved Spirometry for the RETHINC Study Group. 712
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|